ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: Analysis and a comprehensive comparison with other populations

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 6, 2010, Pages 705-712

  Kim, K A ^a   Joo, H J ^a   Park, J Y ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

ABCG2; BCRP; ethnic difference; Koreans; pharmacogenetics; pyrosequencing

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN;

ARTICLE; ETHNICITY; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; KOREA; POPULATION RESEARCH; PYROSEQUENCING;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, NEOPLASM; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 78449308869     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01127.x     Document Type: Article

References (41)

1. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M, (1998) A human placenta-specific ATP-binding scassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Research, 58, 5337-5339.
2. Doyle LA, Yang W, Abruzzo LV, et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 15665-15670.
3. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD, (2001) Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochimica et Biophysica Acta, 1520, 234-241.
4. Litman T, Druley TE, Stein WD, Bates SE, (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cellular and Molecular Life Sciences, 58, 931-959.
5. Miyake K, Mickley L, Litman T, et al. (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Research, 59, 8-13.
6. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E, (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Research, 62, 5035-5040.
7. Maliepaard M, Scheffer GL, Faneyte IF, et al. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Research, 61, 3458-3464.
8. Ishikawa T, (2009) The role of human ABC transporter ABCG2 (BCRP) in pharmacotherapy. Advanced Drug Delivery Reviews, 61, 1-2.
9. Robey RW, To KK, Polgar O, et al. (2009) ABCG2: a perspective. Advanced Drug Delivery Reviews, 61, 3-13.
10. Jonker JW, Smit JW, Brinkhuis RF, et al. (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute, 92, 1651-1656.
11. Honjo Y, Hrycyna CA, Yan QW, et al. (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Research, 61, 6635-6639.
12. Mitomo H, Kato R, Ito A, et al. (2003) A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochemical Journal, 373, 767-774.
13. Sparreboom A, Nooter K, (2000) Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resistance Updates, 3, 357-363.
14. Zamber CP, Lamba JK, Yasuda K, et al. (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics, 13, 19-28.
15. Imai Y, Nakane M, Kage K, et al. (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Molecular Cancer Therpeutics, 1, 611-616.
16. Kondo C, Suzuki H, Itoda M, et al. (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharmaceutical Research, 21, 1895-1903.
17. Tamura A, Watanabe M, Saito H, et al. (2006) Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Molecular Pharmacology, 70, 287-296.
18. Tamura A, Wakabayashi K, Onishi Y, et al. (2007) Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Science, 98, 231-239.
19. Mizuarai S, Aozasa N, Kotani H, (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. International Journal of Cancer, 109, 238-246.
20. Ronaghi M, Uhlen M, Nyren P, (1998) A sequencing method based on real-time pyrophosphate. Science, 281, 363, 365.
21. Pati N, Schowinsky V, Kokanovic O, Magnuson V, Ghosh S, (2004) A comparison between SNaPshot, pyrosequencing, and biplex invader SNP genotyping methods: accuracy, cost, and throughput. Journal of Biochemical and Biophysical Methods, 60, 1-12.
22. De Jong FA, Marsh S, Mathijssen RH, et al. (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clinical Cancer Research, 10, 5889-5894.
23. Lee SS, Jeong HE, Yi JM, et al. (2007) Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metabolism and Disposition, 35, 623-632.
24. Kim KA, Park PW, Park JY, (2008) Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. European Journal of Clinical Pharmacology, 64, 589-597.
25. Kim KA, Park PW, Hong SJ, Park JY, (2008) The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clinical Pharmacology and Therapeutics, 84, 236-242.
26. Meissner K, Heydrich B, Jedlitschky G, et al. (2006) The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. Journal of Histochemistry and Cytochemistry, 54, 215-221.
27. Kobayashi D, Ieiri I, Hirota T, et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metabolism and Disposition, 33, 94-101.
28. Li J, Cusatis G, Brahmer J, et al. (2007) Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biology and Therapy, 6, 432-438.
29. Sparreboom A, Loos WJ, Burger H, et al. (2005) Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biology and Therapy, 4, 650-658.
30. Sparreboom A, Gelderblom H, Marsh S, et al. (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clinical Pharmacology and Therapeutics, 76, 38-44.
31. Urquhart BL, Ware JA, Tirona RG, et al. (2008) Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenetics Genomics, 18, 439-448.
32. Ito K, Suzuki H, Horie T, Sugiyama Y, (2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharmaceutical Research, 22, 1559-1577.
33. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, et al. (2006) Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metabolism and Disposition, 34, 524-533.
34. Cascorbi I, (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacology and Therapeutics, 112, 457-473.
35. Morisaki K, Robey RW, Ozvegy-Laczka C, et al. (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemotherapy and Pharmacology, 56, 161-172.
36. Backstrom G, Taipalensuu J, Melhus H, et al. (2003) Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. European Journal of Pharmaceutical Sciences, 18, 359-364.
37. Bosch TM, Kjellberg LM, Bouwers A, et al. (2005) Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. American Journal of Pharmacogenomics, 5, 123-131.
38. Boger CA, Stubanus M, Haak T, et al. (2007) Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrology, Dialysis, Transplantation, 22, 154-162.
39. Boger CA, Gotz AK, Kruger B, et al. (2005) Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. European Journal of Medical Research, 10, 161-168.
40. Pourmand N, Elahi E, Davis RW, Ronaghi M, (2002) Multiplex pyrosequencing. Nucleic Acids Research, 30, e31.
41. Eriksson S, Berg LM, Wadelius M, Alderborn A, (2002) Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. Assay Drug Development Technology, 1, 49-59.